The 20th WHO Expert Committee meeting on the selection and use of essential medicines has recommended the inclusion of five medicines (bedaquiline, delamanid, linezolid, rifapentine and terizidone) in the anti- tuberculosis (TB) medicines section of the WHO Model List of Essential Medicines (EML). Rifapentine is indicated for the treatment of latent TB infection (LTBI). The other four medicines are used as part of treatment regimens for multidrug and extensively drug-resistant TB (MDR-TB and XDR-TB respectively), two conditions with high lethality and poor treatment outcomes. Bedaquiline and delamanid are two new drugs which have recently been granted conditional approval by stringent regulatory authorities for use in the treatment of MDR-TB. Linezolid and terizidone are old drugs and their off-label use for severe forms of drug-resistant TB has now also been approved by the EML.
06 March 2015 | Geneva | There is much to celebrate, this International Women’s Day. The empowerment of women is gaining ground globally, more girls are in school and the world is mobilizing to ensure that they have a healthier and safer future to reach their full potential. However, despite these successes, millions of women still face barriers and inequalities in many areas of their lives, including in health. This is evident in the battle women face against tuberculosis (TB).
25 FEBRUARY 2015 ¦ GENEVA - Over ninety representatives from countries, technical agencies, financing partners, the corporate sector as well as civil society, are meeting together in Geneva over the next two days for a first-ever consultation on the role of electronic and mobile health (e/mHealth) interventions in TB and tobacco control. This consultation has been organized by the World Health Organization's (WHO) Global TB Programme and Department for the Prevention of Noncommunicable Diseases with the European Respiratory Society (ERS).
20 JANUARY 2015 | Geneva | The Global TB Programme welcomes the decision by United Nations Secretary-General Ban Ki-moon to appoint Dr Eric P Goosby as the new UN Special Envoy on Tuberculosis (TB). Special Envoy Goosby brings a wealth of experience to the fight against this pressing infectious disease crisis which still claims millions of lives each year. “We are extremely pleased with the appointment of Special Envoy Goosby”, said Dr Mario Raviglione, Director of the WHO Global TB Programme. “Eric has been with us fighting against TB for many years and has mobilized much-needed resources to strengthen its care and control. Our WHO efforts to end TB will receive a much higher profile with Eric’s engagement”.
37 millionlives were saved through effective diagnosis and treatment, 2000-2013.Fact sheet on tuberculosis
480 000people developed multidrug-resistant tuberculosis (MDR-TB) in the world in 2013.Q&A on MDR-TB
2 billionUS dollars per year needed to fill resource gap for implementing existing TB interventions.Information note on Global TB report 2014
ToBe Continued World TB Day
Sounds from Stazione di Topolò/Global Health Incubator across the World and back
ToBe Continued is coming back on March 24th, World TB Day ToBe Continued is an original concert lasting 24 hours (un-interrupted 24 hour marathon- from 00.00 hours to the midnight of March 24th, GMT+1), during which musicians from many parts of the World will be connected to a website that will broadcast their concerts. The event, that will cover the 24th of March, World TB Day, in its entirety, is coordinated by Antonio Della Marina, musician and computer music composer, and by Moreno Miorelli, artistic director of the annual gathering "Stazione di Topolò/Postaja Topolove".
- Tuberculosis fact sheet
- More fact sheets on TB
- 10 facts on tuberculosis
- What is TB? How is it treated?
- What is multidrug-resistant tuberculosis and how do we control it?
- Restoring hope in Swaziland: helping stop TB through earlier diagnosis
- Viet Nam: optimism for multidrug-resistant TB patients
- More feature stories